| First Author | Reissig S | Year | 2012 |
| Journal | J Immunol | Volume | 189 |
| Issue | 10 | Pages | 4770-6 |
| PubMed ID | 23066153 | Mgi Jnum | J:190708 |
| Mgi Id | MGI:5449492 | Doi | 10.4049/jimmunol.1201993 |
| Citation | Reissig S, et al. (2012) The tumor suppressor CYLD controls the function of murine regulatory T cells. J Immunol 189(10):4770-6 |
| abstractText | CYLD was originally identified as a tumor suppressor gene mutated in familial cylindromatosis, an autosomal dominant predisposition to multiple benign neoplasms of the skin known as cylindromas. The CYLD protein is a deubiquitinating enzyme that acts as a negative regulator of NF-kappaB and JNK signaling through its interaction with NEMO and TNFR-associated factor 2. We have previously described a novel mouse strain that expresses solely and excessively a naturally occurring splice variant of CYLD (CYLD(ex7/8)). In this study, we demonstrate that CYLD plays a critical role in Treg development and function. T cells of CYLD(ex7/8) mice had a hyperactive phenotype manifested by increased production of inflammatory cytokines and constitutive activation of the NF-kappaB pathway. Furthermore, the amount of Foxp3(+) regulatory T cells in these mice was markedly enhanced in thymus and peripheral organs. Importantly, these regulatory T cells displayed decreased expression levels of CD25 and CTLA-4 associated with impaired suppressive capacity. Hence, our data emphasize an essential role of CYLD in maintaining T cell homeostasis as well as normal T regulatory cell function, thereby controlling abnormal T cell responses. |
